Project Grant R43AA018600

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is focused on exploring the potential of anti-viral drugs, specifically the hepatitis C virus (HCV) NS5A inhibitors elbasvir (ELB) and daclatasvir (DAC), to sensitize and re-sensitize various cancer types to chemotherapy treatments. The $472,355 award, spanning June 2024 to May 2029, will support research conducted by The Methodist Hospital Research Institute (HMRI) in Houston, Texas....

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), seeks to implement a low-threshold Hepatitis C (HCV) treatment program in a jail setting. The $252,042 award, effective September 15, 2024, aims to pilot the "MINMON-J" approach, which modifies a low-barrier HCV treatment protocol for the jail environment. The key products and services to be delivered under this grant include: Evaluating...

This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $502,043 to support a 5-year research program at Brandeis University. The research aims to bridge gaps in understanding how metal ions (Fe, Mn, Zn) affect the function of two key enzyme superfamilies: viral proteases and SAMHD1 dNTPases. Specifically, the research will: Dissect the metal-dependent activities of viral proteases...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $624,001 to New York University School of Medicine to develop a novel class of molecules called Multivalent Peptoid Conjugates (MPCs) that can antagonize the androgen receptor (AR) and stop the growth of prostate cancer cells resistant to standard anti-androgen treatments. The key focus is on using a peptoid scaffold to create these MPC molecules, which exhibit favorable pharmacological...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $421,744 to the Regents of the University of Michigan to develop a peptide multimer for early detection of hepatocellular carcinoma (HCC) using advanced imaging techniques. The key products and services to be delivered under this grant include: Identification of promising early-stage HCC target biomarkers through single-cell RNA sequencing and molecular pathogenesis...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $793,324 to the Beckman Research Institute of the City of Hope to develop selective small molecule inhibitors targeting the CYP8B1 enzyme for the treatment of hepatocellular carcinoma (HCC). The key objectives are to: 1) identify CYP8B1 inhibitors through high-throughput screening, 2) validate hit compounds for potency, specificity, and structure-activity relationships, and 3)...

The Department of the Army Medical Command awarded a $5.5 million Project Grant to Carogen Corporation to support the Combination of HBV Immunotherapy with shRNA-Mediated PD-1/PDL Checkpoint Inhibition for Treatment of Chronic HBV from September 15, 2022 through September 14, 2025. This funding supports research under the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research and develop...

This $483,591 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) aims to develop novel, biologic RNA molecules to modulate metabolism in hepatocellular carcinoma (HCC), the most common form of liver cancer. The University of California, Davis will conduct this 5-year research project to: 1) design, clone, express, and purify a focused group of novel humanized biologic RNA (bioRNA) molecules targeting HCC; 2) delineate the mechanisms by...

The University of Massachusetts (UMass) was awarded a $402,147 Project Grant under the National Cancer Institute's Cancer Treatment Research Program (CFDA 93.395) to develop a bacterial vector to deliver oncolytic viruses (OVs) to hepatocellular carcinoma tumors. The goal is to use the virus-delivering Salmonella (VDS) to carry the H-1 parvovirus (H-1PV) into cancer cells, protecting the viral genome from clearance in the blood and enabling targeted delivery to solid tumors. The project aims...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Brigham & Women's Hospital Inc. a $884,453 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a rapid, cost-effective point-of-care (POC) diagnostic device for detecting hepatitis C virus (HCV) infection. The grant aims to address the critical need for improved HCV screening capabilities, particularly among underserved populations like American Indian and Alaska Native...